NCT00511082 - Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

July 31, 2010

Conditions

Non-Hodgkin's Lymphoma(NHL)Multiple Myeloma

Interventions

DRUG

OPB-31121

100-mg tablet Dose: OPB-31121 50, 100, 200, 400, 600, 800, and 1000 mg Dosage regimen: ingestion with water after breakfast Treatment period: 4 weeks Mode of Administration: oral administration of OPB-31121 once daily

Trial Locations (1)

Unknown

Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong